Core Viewpoint - The stock price of Weikang Pharmaceutical has experienced significant fluctuations, with a year-to-date increase of 75.45% and a recent decline of 2.13% on November 6, 2023 [1][2]. Financial Performance - For the period from January to September 2025, Weikang Pharmaceutical reported a revenue of 151 million yuan, representing a year-on-year decrease of 59.20%. The net profit attributable to the parent company was -124 million yuan, a decline of 380.87% compared to the previous year [2]. - Cumulative cash distribution since the A-share listing amounts to 179 million yuan, with 55.4 million yuan distributed over the past three years [3]. Stock Market Activity - The stock has seen a 14.21% increase over the last five trading days and a 17.59% increase over the last 20 days [2]. - As of September 30, 2023, the number of shareholders increased to 10,600, up by 7.09%, while the average circulating shares per person decreased by 6.62% to 13,605 shares [2]. Company Overview - Weikang Pharmaceutical, established on March 31, 2000, and listed on August 24, 2020, is located in Lishui Economic Development Zone, Zhejiang Province. The company focuses on the research, production, and sales of modern Chinese and Western medicines, with 97.16% of its revenue coming from traditional and Western medicine products [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the Chinese medicine sub-sector, and is associated with concepts such as small-cap stocks, private hospitals, anti-influenza, and pharmaceutical e-commerce [2]. Trading Activity - On November 6, 2023, Weikang Pharmaceutical's stock price was 26.20 yuan per share, with a trading volume of 30.83 million yuan and a turnover rate of 0.81%. The total market capitalization stood at 3.794 billion yuan [1]. - The net inflow of main funds was 248,000 yuan, with significant selling activity amounting to 1.279 million yuan [1].

Core Viewpoint - 康希诺's stock price has experienced fluctuations, with a year-to-date increase of 23.14% but a recent decline over various trading periods, indicating potential volatility in the market [2]. Company Overview - 康希诺, established on January 13, 2009, and listed on August 13, 2020, is located in Tianjin Economic-Technological Development Area and focuses on the research, production, and commercialization of innovative vaccines that meet both Chinese and international standards [2]. - The company's main revenue source is vaccine and related product sales, accounting for 97.84% of total revenue, with other income contributing 2.16% [2]. Financial Performance - For the period from January to September 2025, 康希诺 reported a revenue of 693 million yuan, representing a year-on-year growth of 22.13%, while the net profit attributable to shareholders was 14.44 million yuan, showing a significant increase of 106.49% [2]. - Since its A-share listing, 康希诺 has distributed a total of 198 million yuan in dividends, with no dividends paid in the last three years [3]. Shareholder Information - As of September 30, 2025, 康希诺 had 17,700 shareholders, an increase of 1.07% from the previous period, with an average of 0 circulating shares per shareholder [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 1.3566 million shares as a new shareholder [3]. Market Activity - On November 5, 康希诺's stock price fell by 2.02%, trading at 75.18 yuan per share, with a total market capitalization of 18.603 billion yuan [1]. - The stock has seen a net inflow of 561,000 yuan from major funds, with significant buying and selling activity recorded [1].

Core Points - Guizhou Bailing's stock price increased by 2.25% on November 5, reaching 5.92 CNY per share, with a total market capitalization of 8.274 billion CNY [1] - The company has seen a year-to-date stock price increase of 53.77%, with a recent 20-day increase of 12.76% [1] - For the period from January to September 2025, Guizhou Bailing reported a revenue of 2.102 billion CNY, a year-on-year decrease of 24.28%, and a net profit of 56.8144 million CNY, down 35.60% year-on-year [2] Financial Performance - The company has a main business revenue composition of 86.97% from traditional Chinese medicine, 8.44% from Western medicine, 2.27% from medical services, and 1.91% from other sources [1] - Cumulative cash dividends since the A-share listing amount to 1.447 billion CNY, with no dividends paid in the last three years [3] Shareholder Information - As of October 20, 2025, the number of shareholders increased to 96,300, with an average of 12,597 circulating shares per person, a decrease of 13.19% [2] - Hong Kong Central Clearing Limited is the fourth largest circulating shareholder, holding 14.0733 million shares as a new shareholder [3]

Core Viewpoint - The stock price of Shuoshi Biotechnology has experienced fluctuations, with a year-to-date increase of 85.86% but a recent decline of 2.86% over the past five trading days [2] Group 1: Stock Performance - As of November 4, Shuoshi Biotechnology's stock price was 76.21 CNY per share, with a market capitalization of 6.392 billion CNY [1] - The stock has seen a year-to-date increase of 85.86%, a 2.86% decline in the last five trading days, a 19.26% increase over the last 20 days, and a 36.60% increase over the last 60 days [2] - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 19.7845 million CNY on February 17 [2] Group 2: Financial Performance - For the period from January to September 2025, Shuoshi Biotechnology reported revenue of 258 million CNY, a year-on-year decrease of 3.95%, and a net profit attributable to shareholders of 3.1517 million CNY, down 88.38% year-on-year [3] - The company has distributed a total of 1.37 billion CNY in dividends since its A-share listing, with 285 million CNY distributed over the past three years [4] Group 3: Shareholder Information - As of October 20, 2025, the number of shareholders for Shuoshi Biotechnology was 7,620, a decrease of 0.94% from the previous period, while the average circulating shares per person increased by 0.94% to 11,006 shares [3] - As of September 30, 2025, one of the top ten circulating shareholders, 华夏行业景气混合A (003567), has exited the list [4] Group 4: Business Overview - Shuoshi Biotechnology, established on April 12, 2010, and listed on December 5, 2019, specializes in the research, production, and sales of in vitro diagnostic products, including diagnostic reagents and supporting testing instruments [2] - The company's main revenue sources are diagnostic reagents (85.89%), purchased instruments and materials (7.19%), testing instruments (3.84%), testing services (2.24%), and others (0.84%) [2] - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [2]

Core Viewpoint - Yiling Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 11.71% [1] Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%, while net profit attributable to shareholders was 1 billion yuan, reflecting a year-on-year increase of 80.33% [2] Stock Market Activity - As of November 4, 2025, Yiling Pharmaceutical's stock price was 17.55 yuan per share, with a market capitalization of 29.321 billion yuan. The stock has seen a trading volume of 253 million yuan and a turnover rate of 1.04% [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 64.05 million yuan on January 6 [1] Shareholder Information - As of September 30, 2025, the number of shareholders was 152,700, a decrease of 10.22% from the previous period, with an average of 9,013 circulating shares per person, an increase of 11.38% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 8.1119 million shares, and a new shareholder, Changxin Jinli Trend Mixed A, holding 5.95 million shares [3] Dividend Distribution - Yiling Pharmaceutical has distributed a total of 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed in the last three years [3] Industry Classification - Yiling Pharmaceutical is classified under the pharmaceutical and biological sector, specifically in traditional Chinese medicine [2]

11月3日，康希诺盘中下跌2.02%，截至09:57，报77.56元/股，成交4553.05万元，换手率0.51%，总市值 191.92亿元。 资金流向方面，主力资金净流出147.16万元，特大单买入0.00元，占比0.00%，卖出188.73万元，占比 4.15%；大单买入833.87万元，占比18.31%，卖出792.30万元，占比17.40%。 康希诺今年以来股价涨27.04%，近5个交易日涨3.95%，近20日涨1.52%，近60日跌2.82%。 分红方面，康希诺A股上市后累计派现1.98亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，康希诺十大流通股东中，香港中央结算有限公司位居第十大流通 股东，持股135.66万股，为新进股东。 责任编辑：小浪快报 康希诺所属申万行业为：医药生物-生物制品-疫苗。所属概念板块包括：猴痘概念、生物医药、疫苗、 抗流感、中盘等。 截至9月30日，康希诺股东户数1.77万，较上期增加1.07%；人均流通股0股，较上期增加0.00%。2025年 1月-9月，康希诺实现营业收入6.93亿元，同比增长22.13%；归母净利润1444.01万元，同比 ...

Core Viewpoint - The stock of Jindike experienced a decline of 2.14% on November 3, trading at 16.93 CNY per share, with a total market capitalization of 2.086 billion CNY. The company has seen a year-to-date stock price increase of 39.69% [1] Financial Performance - For the period from January to September 2025, Jindike achieved operating revenue of 74.6576 million CNY, representing a year-on-year growth of 91.93%. However, the net profit attributable to shareholders was -86.4706 million CNY, a decrease of 61.74% compared to the previous year [1] Stock Market Activity - As of November 3, the trading volume was 18.9898 million CNY, with a turnover rate of 0.90%. The net outflow of main funds was 2.6402 million CNY, with large single purchases accounting for 15.89% and sales for 29.79% of the total [1] Shareholder Information - As of September 30, the number of shareholders for Jindike was 4,319, a decrease of 4.55% from the previous period. The average circulating shares per person increased by 4.77% to 28,525 shares [1] Company Overview - Jindike, established on December 29, 2008, and listed on August 2, 2021, is a biopharmaceutical company based in Taizhou, Jiangsu Province, focusing on the research, production, and sales of human vaccines. The company's main business revenue is derived entirely from vaccine products [1] Dividend Information - Since its A-share listing, Jindike has distributed a total of 61.6 million CNY in dividends, with 17.6 million CNY distributed over the past three years [2]

Core Viewpoint - Chenxin Pharmaceutical is a well-established chemical drug manufacturer in China, with a strong focus on research and development, and has been listed on the Shanghai Stock Exchange since 2017 [1] Group 1: Business Performance - In Q3 2025, Chenxin Pharmaceutical achieved a revenue of 2.584 billion yuan, ranking 27th among 110 companies in the industry, with the industry leader, East China Pharmaceutical, generating 32.664 billion yuan [2] - The company's net profit for the same period was 385 million yuan, placing it 21st in the industry, while the top performer, Hengrui Medicine, reported a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Chenxin Pharmaceutical's debt-to-asset ratio was 18.72%, down from 21.48% year-on-year, significantly lower than the industry average of 35.26%, indicating strong solvency [3] - The company's gross profit margin stood at 55.08%, slightly below the industry average of 57.17%, reflecting a competitive profitability position [3] Group 3: Executive Compensation - The chairman and general manager, Du Zhenxin, received a salary of 1.1628 million yuan in 2024, an increase of 191,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 14.38% to 30,800, while the average number of circulating A-shares held per shareholder increased by 16.79% to 14,700 [5]

Core Insights - Lianhuan Pharmaceutical, established in 2000 and listed in 2003, focuses on the research, production, and sales of chemical pharmaceuticals, with a diverse product line and mature production processes [1] Financial Performance - For Q3 2025, Lianhuan Pharmaceutical reported revenue of 2.082 billion yuan, ranking 31st out of 110 in the industry, while the industry leader, East China Pharmaceutical, generated 32.664 billion yuan [2] - The company incurred a net loss of 27.7224 million yuan, ranking 79th in the industry, with the top performer, Heng Rui Pharmaceutical, achieving a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, Lianhuan Pharmaceutical's debt-to-asset ratio was 57.72%, up from 47.92% the previous year, exceeding the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 34.49%, down from 49.89% year-on-year, and below the industry average of 57.17% [3] Executive Compensation - The chairman, Qian Zhenhua, received a salary of 791,500 yuan in 2024, an increase of 31,200 yuan from 2023 [4] - The general manager, Niu Ben, earned 775,500 yuan in 2024, up by 65,700 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 54.72% to 46,600 [5] - The average number of circulating A-shares held per shareholder decreased by 35.37% to 6,130.67 [5]

Core Viewpoint - Duori Pharmaceutical, established in December 2016 and listed on the Shenzhen Stock Exchange in September 2021, focuses on the research and development of chemical drug formulations and has several core technologies in this field [1] Business Performance - For Q3 2025, Duori Pharmaceutical reported revenue of 137 million, ranking 103rd among 110 companies in the industry, significantly lower than the industry leader, East China Pharmaceutical, which had revenue of 32.664 billion, and the industry average of 2.8 billion [2] - The net profit for the same period was -113 million, placing the company 96th in the industry, while the top performer, Hengrui Medicine, achieved a net profit of 5.76 billion, with the industry average at 299 million [2] Financial Ratios - As of Q3 2025, Duori Pharmaceutical's debt-to-asset ratio was 55.73%, an increase from 28.40% in the previous year and above the industry average of 35.26%, indicating increased debt pressure [3] - The gross profit margin for Q3 2025 was 4.63%, a significant drop from 40.75% in the previous year and below the industry average of 57.17%, reflecting weak profitability [3] Executive Compensation - The chairman and general manager, Deng Yong, received a salary of 609,000 in 2024, a decrease of 31,200 from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 16.60% to 6,361, while the average number of circulating A-shares held per account increased by 19.90% to 12,600 [5]